In contrast, TLR7 and TLR9 agonists are potent drivers of anti-tumor macrophages, and these macrophages in turn secrete pro-inflammatory cytokines including IL-12 and type 1 interferon to activate CD8+T cells highlighting a therapeutic potential to use different TLR agonists to cause a synergistic effect [142]. Here, CD8A is linked to neoplasm.